Nadolol
Beta Blocking Agents, Non-Selective
- Drug class
- Beta Blocking Agents, Non-Selective
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 10
- FDA reports (12 mo)
- 226
Overview
Plain-language summary, compiled from the cited regulatory records
Nadolol is a medication classified as a non-selective beta-blocking agent [1]. It is approved for the long-term management of patients experiencing angina pectoris [1]. Additionally, Nadolol tablets are indicated for the treatment of hypertension, aiming to lower blood pressure [1]. Reducing blood pressure is known to decrease the risk of cardiovascular events, such as strokes and heart attacks [1].
In the past 12 months, there have been 226 adverse event reports associated with Nadolol [2]. The most frequently reported events include "Drug Ineffective," "Off Label Use," "Headache," "Chronic Sinusitis," and "Macular Degeneration" [2]. Nadolol is available under various brand names [1].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| CA Canada | Health Canada | 5 | March 28, 2025 |
| US United States | FDA | 4 | April 9, 2025 |
| GB United Kingdom | MHRA | 1 | March 13, 2026 |
CACanada· Health Canada
5 products
Uses
Angina:
APO-NADOLOL (nadolol) is indicated for prophylaxis of angina pectoris.
Hypertension:
APO-NADOLOL is indicated in patients with mild or moderate hypertension. APO-NADOLOL is usually used in combination with other drugs, particularly a thiazide diuretic. However, it may be tried alone as an initial agent in those patients in whom, in the judgment of the physician, treatment should be started with a beta-blocker rather than a diuretic.
The combination of nadolol with a diuretic has been found to be compatible and generally more effective than nadolol alone. In a few cases where peripheral vasodilators were used with nadolol, no evidence of incompatibility was seen.
APO-NADOLOL is not recommended for the emergency treatment of hypertensive crises. Page 5 of
USUnited States· FDA
4 products
Uses
INDICATIONS AND USAGE
Angina Pectoris Nadolol tablets, USP are indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Nadolol.
Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake.
Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
GBUnited Kingdom· MHRA
1 product
Uses
Nadolol is indicated in the management of:
Angina Pectoris: For the long-term management of patients with angina pectoris by continuous medication.
Hypertension:
For the long-term management of essential hypertension, either alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.
Arrhythmias:
For the treatment of cardiac tachyarrhythmias.
Migraine:
For the prophylactic management of migraine headache. The efficacy of Nadolol in the treatment of a migraine attack that has already started has not been established, and Nadolol is not indicated for such use.
Thyrotoxicosis:
Drug interactions
Known interactions involving Nadolol. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 517. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]Health Canada (DPD) · 00782467 · revised March 28, 2025
- [2]FDA DailyMed · 0a2acdc0-aab6-46… · revised May 28, 2024 [PDF]
- [3]MHRA (UK) · PL450430062 · revised March 13, 2026
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.